UBS Maintains Buy on Surgery Partners, Lowers Price Target to $21
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst A.J. Rice maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $29 to $21.
UBS analyst A.J. Rice maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $29 to $21.